What's New

News

2023/12/15
NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
2023/10/19
Updated information of sustainability
2023/10/18
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/09/25
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. PDF
2022/11/16
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody PDF
2021/06/30
New Late-Breaking Data at The American Diabetes Association Show GlycoMark May Be an Effective Test for COVID-19 Severity PDF
2020/07/06
Pict Leap Co., Ltd has developed “ Liquid Crystal Display Which Can Be Photographed By Infrared Camera ” PDF
2020/02/07
Pict Leap Co., Ltd has developed "32-inch off-grid outdoor display system PDF
2019/11/22
Nippon Kayaku launches Portrazza Injection, a human anti EGFR Monoclonal Antibody
2019/10/01
MicroChem Corp (MCC) has changed its name to Kayaku Advanced Materials, Inc.(KAM)
2019/08/21
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Dosage & Administration of Breast Cancer with HER2 Overexpression
2019/06/18
Transfer of Marketing Authorization for humanized anti EGFR Monoclonal Antibody PORTRAZZA, in JAPAN
2019/05/30
Management Changes (Appointments & Transfers)
2019/04/22
NIPPON KAYAKU and Eli Lilly Enter into Licensing Agreement of Necitumumab, a humanized anti EGFR Monoclonal Antibody, in JAPAN
PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Sustainability